Clinical Trial Update: Omadacycline vs Moxifloxacin for the Treatment of CABP (EudraCT #2013-004071-13) [Phase 3]

View source ↗

Summary

Phase 3 trial comparing omadacycline to moxifloxacin for community-acquired bacterial pneumonia has completed with results posted in 2018.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Community-acquired Bacterial Pneumonia

Drugs mentioned

• Moxifloxacin (moxifloxacin)
• Omadacycline (omadacycline)

Snippet

Sponsor: Paratek Pharmaceuticals Inc | Conditions: Bacterial Pneumonia, Community-Acquired Infections | Phase 3 | Status: COMPLETED | Results posted: 2018-11-29